Neurological Surgery 脳神経外科50巻1号

2022年01月発行

特集 Precision Medicine—個別化医療を目指した遺伝子診断と新治療の知見 Ⅲ脳血管障害

脳動静脈奇形

著者： 髙木康志¹

所属機関： ¹徳島大学大学院医歯薬学研究部脳神経外科学

ページ範囲：P.196 - P.204

Point
・孤発脳動静脈奇形の血管壁内皮細胞においてKRAS遺伝子の変異が高率に認められることが発見され，これを標的とした薬物治療の可能性が提示されている．
・脳動静脈奇形の外科的治療では症例を1例1例詳細に検討し，安全な摘出術を施行することが重要である．

参考文献

1）Kader A, et al：Recurrent cerebral arteriovenous malformations after negative postoperative angiograms. J Neurosurg 85：14-18, 1996

2）Peterson K, et al：Somatic mosaicism in the pathogenesis of de novo cerebral arteriovenous malformations：a paradigm shift implicating the RAS-MAPK signaling cascade. Cerebrovasc Dis 50：231-238, 2021

3）Sonstein WJ, et al：Expression of vascular endothelial growth factor in pediatric and adult cerebral arteriovenous malformations：an immunocytochemical study. J Neurosurg 85：838-845, 1996

4）Sure U, et al：Endothelial proliferation, neoangiogenesis, and potential de novo generation of cerebrovascular malformations. J Neurosurg 94：972-977, 2001

5）Wang K, et al：Perturbations of BMP/TGF-β and VEGF/VEGFR signalling pathways in non-syndromic sporadic brain arteriovenous malformations（BAVM）. J Med Genet 55：675-684, 2018

6）Coultas L, et al：Endothelial cells and VEGF in vascular development. Nature 438：937-945, 2005

7）Yildirim O, et al：Expression of platelet-derived growth factor ligand and receptor in cerebral arteriovenous and cavernous malformations. J Clin Neurosci 17：1557-1562, 2010

8）Carlson TR, et al：Endothelial expression of constitutively active Notch4 elicits reversible arteriovenous malformations in adult mice. Proc Natl Acad Sci U S A 102：9884-9889, 2005

9）Kuijper S, et al：Regulation of angiogenesis by Eph-ephrin interactions. Trends Cardiovasc Med 17：145-151, 2007

10）Lawson ND, et al：Sonic hedgehog and vascular endothelial growth factor act upstream of the Notch pathway during arterial endothelial differentiation. Dev Cell 3：127-136, 2002

11）Nikolaev SI, et al：Somatic activating KRAS mutations in arteriovenous malformations of the brain. N Engl J Med 378：250-261, 2018

12）Al-Olabi L, et al：Mosaic RAS/MAPK variants cause sporadic vascular malformations which respond to targeted therapy. J Clin Invest 128：1496-1508, 2018

13）Hong T, et al：High prevalence of KRAS/BRAF somatic mutations in brain and spinal cord arteriovenous malformations. Brain 142：23-34, 2019

14）Goss JA, et al：Somatic mutations in intracranial arteriovenous malformations. PLoS One 14：e0226852, 2019

15）Priemer DS, et al：Activating KRAS mutations in arteriovenous malformations of the brain：frequency and clinicopathologic correlation. Hum Pathol 89：33-39, 2019

16）Oka M, et al：KRAS G12D or G12V mutation in human brain arteriovenous malformations. World Neurosurg 126：e1365-e1373, 2019

17）Hermanto Y, et al：Histopathological features of brain arteriovenous malformations in Japanese patients. Neurol Med Chir（Tokyo）56：340-344, 2016

18）Takagi Y, et al：Basic research and surgical techniques for brain arteriovenous malformations. J Med Invest 67：222-228, 2020

19）Takagi Y, et al：DNA fragmentation in central nervous system vascular malformations. Acta Neurochir（Wien）142：987-994, 2000

20）Takagi Y, et al：Proliferative activity through extracellular signal-regulated kinase of smooth muscle cells in vascular walls of cerebral arteriovenous malformations. Neurosurgery 58：740-748；discussion 740-748, 2006

21）Aziz MM, et al：Activation of nuclear factor κB in cerebral arteriovenous malformations. Neurosurgery 67：1669-1679；discussion 1679-1680, 2010

22）Aziz MM, et al：Expression and activation of STAT family proteins in cerebral arteriovenous malformations. World Neurosurg 78：487-497, 2012

23）Takagi Y, et al：Early regrowth of juvenile cerebral arteriovenous malformations：report of 3 cases and immunohistochemical analysis. World Neurosurg 73：100-107, 2010

24）Takagi Y, et al：Differential gene expression in relation to the clinical characteristics of human brain arteriovenous malformations. Neurol Med Chir（Tokyo）54：163-175, 2014

25）Dhillon AS, et al：MAP kinase signalling pathways in cancer. Oncogene 26：3279-3290, 2007

26）Eerola I, et al：Capillary malformation-arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations. Am J Hum Genet 73：1240-1249, 2003

27）Amyere M, et al：Germline loss-of-function mutations in EPHB4 cause a second form of capillary malformation-arteriovenous malformation（CM-AVM2）deregulating RAS-MAPK signaling. Circulation 136：1037-1048, 2017

28）Couto JA, et al：Somatic MAP2K1 mutations are associated with extracranial arteriovenous malformation. Am J Hum Genet 100：546-554, 2017

29）Goss JA, et al：Intramuscular fast-flow vascular anomaly contains somatic MAP2K1 and KRAS mutations. Angiogenesis 22：547-552, 2019

30）Fish JE, et al：Somatic gain of KRAS function in the endothelium is sufficient to cause vascular malformations that require MEK but not PI3K signaling. Circ Res 127：727-743, 2020

31）Guttmacher AE, et al：Hereditary hemorrhagic telangiectasia. N Engl J Med 333：918-924, 1995

32）McDonald J, et al：Hereditary hemorrhagic telangiectasia：an overview of diagnosis, management, and pathogenesis. Genet Med 13：607-616, 2011

33）McAllister KA, et al：Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 8：345-351, 1994

34）Patel BG, et al：Initial experience with combined BRAF and MEK inhibition with stereotactic radiosurgery for BRAF mutant melanoma brain metastases. Melanoma Res 26：382-386, 2016

35）Lekwuttikarn R, et al：Genotype-guided medical treatment of an arteriovenous malformation in a child. JAMA Dermatol 155：256-257, 2019

36）Maynard K, et al：Antiangiogenic agent as a novel treatment for pediatric intracranial arteriovenous malformations：case report. J Neurosurg Pediatr 4：1-7, 2019

37）Mohr JP, et al；international ARUBA investigators：Medical management with or without interventional therapy for unruptured brain arteriovenous malformations（ARUBA）：a multicentre, non-blinded, randomised trial. Lancet 383：614-621, 2014

38）Al-Shahi Salman R, et al；Scottish Audit of Intracranial Vascular Malformations Collaborators：Outcome after conservative management or intervention for unruptured brain arteriovenous malformations. JAMA 311：1661-1669, 2014

39）Derdeyn CP, et al；American Heart Association Stroke Council：Management of Brain Arteriovenous Malformations：A Scientific Statement for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke 48：e200-e224, 2017

40）Hashimoto N, et al：Surgery of cerebral arteriovenous malformations. Neurosurgery 61（1 Suppl）：375-387；discussion 387-389, 2007

41）髙木康志：術前3Dシミュレーションと術中血流評価により安全に摘出できたeloquent area近傍に存在する非表在性脳動脈静脈奇形の1例．脳外誌 25：259-263, 2016

42）髙木康志，橋本信夫：解剖を中心とした脳神経手術手技 脳動静脈奇形手術の基本手技．No Shinkei Geka 34：1207-1214, 2006

43）髙木康志：AVMに対する治療選択と外科治療の実際．脳外誌 26：117-124, 2017

44）Takagi Y, et al：Evaluation of serial intraoperative surgical microscope-integrated intraoperative near-infrared indocyanine green videoangiography in patients with cerebral arteriovenous malformations. Neurosurgery 70（1 Suppl Operative）：34-42；discussion 42-43, 2012

45）Shimada K, et al：Efficacy of intraarterial superselective indocyanine green videoangiography in cerebral arteriovenous malformation surgery in a hybrid operating room. J Neurosurg 134：1544-1552, 2020

46）髙木康志：脳動静脈奇形治療のエビデンスとリアルワールド．脳外誌 28：142-148, 2019